Journal Mobile Options
Table of Contents
Vol. 217, No. 2, 2008
Issue release date: August 2008

Calcipotriol plus Betamethasone Dipropionate Scalp Formulation Is Effective and Well Tolerated in the Treatment of Scalp Psoriasis: A Phase II Study

Buckley C. · Hoffmann V. · Shapiro J. · Saari S. · Cambazard F. · Milsgaard M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: There is a need for more effective therapy for scalp psoriasis. Objective: To assess the efficacy and safety of a 2-compound scalp formulation including calcipotriol and betamethasone dipropionate in the treatment of scalp psoriasis. Methods: Patients (n = 218) with scalp psoriasis were randomized to treatment with the 2-compound scalp formulation (n = 108) or betamethasone dipropionate in the same vehicle (n = 110). The treatments were applied once daily on the scalp for up to 8 weeks. Results: The 2-compound scalp formulation showed a significantly higher efficacy than betamethasone dipropionate on the total sign score at the end of treatment (p = 0.042) and after 2 weeks (p = 0.005). Conclusion: The calcipotriol plus betamethasone dipropionate scalp formulation was superior to betamethasone dipropionate in the same vehicle when used once daily for up to 8 weeks in the treatment of scalp psoriasis.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Farber EM, Nall ML: The natural history of psoriasis in 5,600 patients. Dermatologica 1974;148:1–18.
  2. Poyner TF, Fell PJ: A survey of patients with plaque psoriasis who had not consulted their doctor in the past year. Br J Clin Res 1995;6:201–207.
  3. van de Kerkhof PCM, Steegers-Theunissen RPM, Kuipers MV: Evaluation of topical drug treatment in psoriasis. Dermatology 1998;197:31–36.
  4. van de Kerkhof PCM, de Hoop D, de Korte J, Kuipers MV: Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998;197:326–334.
  5. Farber EM, Bright RD, Nall ML: Psoriasis: a questionnaire survey of 2,144 patients. Arch Dermatol 1968;98:248–259.
  6. Feldman SR, Housman TS: Patient’s vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003;4:221–224.
  7. Berth-Jones J, Chu AC, Dodd WA, Ganpule M, Griffiths WA, Haydey RP, Klaber MR, Murray SJ, Rogers S, Jurgensen HJ: A multi-centre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992;127:266–271.
  8. Tham SN, Lim KC, Cheong WK: A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994;131:673–677.
  9. Cunliffe WJ, Berth-Jones J, Claudy A, Fairiss G, Goldin D, Gratton D: Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992;26:736–743.
  10. Kragballe K, Gjertsen BT, de Hoop D, Karlsmark T, van de Kerkhof PCM, Larko O, Nieboer C, Roed-Petersen J, Strand A, Tikjob G: Double-blind right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337:193–196.
  11. Ramsay CA, Berth-Jones J, Brundin G, Cunliffe WJ, Dubertret L, van de Kerkhof PCM, Menne T, Wegmann E: Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994;189:260–264.
  12. Ellis JP, Griffiths WAD, Klaber MR: Long-term treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short contact dithranol. Eur J Clin Res 1995;7:247–257.
  13. Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, Rustin M, Downes N: Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994;130:483–487.
  14. Thaçi D, Daiber W, Boehncke WH, Kaufmann R: Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 2001;203:153–156.
  15. Barnes L, Altmeyer P, Forstrom L, Stenstrom MH: Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol 2000;10:199–204.
  16. Hovding G: Treatment of psoriasis of the scalp with betamethasone 17,21-dipropionate plus salicylic acid lotion (‘Diprosalic’). Pharmatherapeutica 1981;3:61–66.
  17. Katz HI, Lindholm JS, Weiss JS, Shavin JS, Morman M, Bressinck R, Cornell R, Pariser DM, Pariser RJ, Weng W, Samsom C: Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 1995;17:390–401.
  18. Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, Fleming C, Heikkila H, Jolliffe D, Peyri J, Svensson A, Toole J, Wozel G: A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155–1160.
  19. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, Douglas WS, Lowson D, Mascaro JM, Murphy GM, Stymne B: A new calcipotriol/betamethasone formulation is a highly effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205:389–393.
  20. Papp KA, Guenther L, Boyden B, Grønhøj Larsen F, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, van de Kerkhof PC, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A: Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48–54.
  21. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ: A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131–135.
  22. Guenther L, van de Kerkhof PCM, Snellman E, Kragballe K, Chu AC, Tegner E, Garcia-Diez A, Springborg J: Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316–323.
  23. Kragballe K, Nørrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM: Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004;150:1167–1173.
  24. van de Kerkhof PC, Wasel N, Kragballe K, Cambazard F, Murray S: A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity. Dermatology 2005;210:294–299.
  25. Augustin M, Peeters P, Radtke M, Moehling U, Lapp C. Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany: a comparison of calcipotriol/betamethasone (Daivobet®/Dovobet®/Taclonex®) once daily and a morning/evening non-fix combination of calcipotriol and betamethasone. Dermatology 2007;215:219–228.
  26. Peeters P, Ortonne JP, Sitbon R, Guignard E: Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology 2005;211:139–145.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50